Roy S. Herbst, MD, Ph.D., Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Director, Center for Thoracic Cancers; Deputy Director, Clinical Affairs; Assistant Dean for Translational Research, Office of the Dean, School of Medicine; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; Associate Cancer Center Director, Translational Science at Yale University. In this video, he speaks about Combination Immunotherapy Improves Outcomes for Patients with Non-small Cell Lung Cancer.
Summary:
COAST is a Phase 2 open-label, multicenter, randomized multidrug platform research comparing the effectiveness and safety of durvalumab alone with durvalumab in combination with new medicines in individuals with locally advanced, unresectable Stage III non-small cell lung cancer (NSCLC).